rs1532278 — CLU CLU Alzheimer's risk variant

CLU and Alzheimer's Disease — Your Brain's Amyloid Clearance Gene

Clusterin (CLU), also known as apolipoprotein J, is the third strongest known genetic risk factor for late-onset Alzheimer's disease after APOE and BIN1. It is a secreted molecular chaperone that binds misfolded proteins — including amyloid-beta (Aβ) — and escorts them out of the brain across the blood-brain barrier. The rs1532278 variant sits in an intronic regulatory region of the CLU gene and is one of the most studied and most robustly replicated Alzheimer's risk loci in the entire human genome.

The Mechanism

CLU exerts its neuroprotective effect through two overlapping pathways. First, secreted clusterin forms stable complexes with Aβ and facilitates its clearance from the brain across the blood-brain barrier¹¹ blood-brain barrier
the highly selective barrier between brain tissue and circulating blood via the LRP2 receptor. Second, CLU inhibits Aβ oligomerization and aggregation directly, preventing the formation of the toxic soluble oligomers that damage synapses before plaques ever appear.

Rs1532278 is located in an intronic open chromatin region — a regulatory element — in glutamatergic (excitatory) neurons. A 2025 study using CRISPR editing of human iPSC-derived neurons showed that only rs1532278 among all CLU locus variants sits in an accessible chromatin region in neurons²² only rs1532278 among all CLU locus variants sits in an accessible chromatin region in neurons
Zhao et al., Molecular Neurodegeneration, 2025. The T allele creates stronger binding for the ISL2 transcription factor, retaining approximately 80% more binding capacity than the C allele. This drives elevated neuronal CLU transcription and secretion.

The protective T allele's downstream effect is measurable: T/T carriers show approximately 40–50% higher CLU mRNA expression in glutamatergic neurons compared to C/C carriers, along with greater dendritic complexity, enhanced synaptic marker expression, and higher neuronal firing frequency. Elevated neuronal CLU promotes neuron-to-astrocyte lipid transfer, increasing astrocytic lipid droplet accumulation and fine-tuning glutamate clearance — a lipid-mediated neuron-glia communication pathway that supports neuronal resilience.

The Evidence

CLU was first identified as an Alzheimer's risk locus in the landmark 2009 Harold et al. GWAS³³ 2009 Harold et al. GWAS
Harold et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics, 2009 (5,964 cases + controls, OR = 0.86 for the protective haplotype). Rs1532278 is in near-complete linkage disequilibrium with rs11136000 (r² = 0.95, D′ = 0.99), the originally reported CLU lead SNP — but rs1532278 shows slightly stronger association with ventricular expansion and Aβ deposition, suggesting it sits closer to the true causal variant.

A 2010 meta-analysis confirmed the CLU association across 15,000+ individuals⁴⁴ confirmed the CLU association across 15,000+ individuals
Jun et al. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci. Archives of Neurology, 2010 (OR = 0.91, 95% CI 0.85–0.96), and showed the CLU effect is independent of APOE ε4 status — unlike PICALM, whose effect is largely confined to ε4 carriers. The 2025 functional study reported an even more significant signal at rs1532278 specifically: OR = 0.905 with p = 3.2 × 10⁻³³ in a large meta-GWAS.

Plasma clusterin levels serve as a biomarker for AD progression. Elevated plasma clusterin in MCI predicted progression to AD with HR = 18.6⁵⁵ Elevated plasma clusterin in MCI predicted progression to AD with HR = 18.6
Jongbloed et al. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease. J Alzheimers Dis, 2015 and correlated with faster cognitive decline (r = −0.38). Notably, C/C homozygotes have higher plasma clusterin concentrations, reflecting a compensatory upregulation in response to reduced brain clearance efficiency.

Practical Actions

Rs1532278 C/C and C/T carriers do not have a pathogenic variant — this is a common risk-modifying SNP, not a disease-causing mutation. The C allele is carried by approximately 86% of people in some form (C/C or C/T). Practical focus for C-allele carriers is on lifestyle factors that support the CLU-Aβ clearance pathway: omega-3 fatty acids support neuronal membrane integrity and reduce neuroinflammation at CLU-relevant pathway nodes; aerobic exercise increases CLU expression in hippocampal tissue; and avoiding chronic sleep deprivation is specifically relevant because Aβ clearance via the glymphatic system is maximally active during deep sleep — a pathway that overlaps functionally with CLU-mediated BBB clearance.

Monitoring cognition from midlife is meaningful for C/C homozygotes: baseline cognitive assessments with standardized tools (MoCA or MMSE) in the 40s–50s provide early-change detection before symptoms are clinically apparent.

Interactions

The strongest known interaction is with APOE. APOE ε4 and CLU risk alleles both impair Aβ clearance through related but distinct mechanisms — APOE via direct Aβ binding competition and receptor-mediated clearance at LRP1, CLU via LRP2 — and carriers of both risk alleles show amplified ventricular expansion rates and accelerated Aβ accumulation in imaging studies. This CLU × APOE interaction is documented in the literature and is a strong candidate for a compound action (see interaction candidates below).

The CLU locus also contains rs9331888 (exon 1) and rs7982 (exon 5), which affect alternative splicing of CLU transcripts in a sex-dependent manner. These three variants are in partial LD and tag different functional effects within the same gene — rs1532278 affects transcription in neurons, rs9331888 affects splicing, and rs7982 affects intron retention primarily in females.